Last reviewed · How we verify
gabapentine — Competitive Intelligence Brief
marketed
Large neutral amino acids transporter small subunit 1, Adenosine receptor A1, Alpha-2A adrenergic receptor
Neuroscience
Small molecule
Live · refreshed every 30 min
Target snapshot
gabapentine (gabapentine) — Dominik Irnich.
Comparator set (1 drugs)
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| gabapentine TARGET | gabapentine | Dominik Irnich | marketed | Large neutral amino acids transporter small subunit 1, Adenosine receptor A1, Alpha-2A adrenergic receptor | ||
| Neurontin | gabapentin | Generic (originally Parke-Davis/Pfizer) | marketed | Gabapentinoid (anticonvulsant/neuropathic pain agent) | Large neutral amino acids transporter small subunit 1, Adenosine receptor A1, Alpha-2A adrenergic receptor | 1993-12-30 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- gabapentine CI watch — RSS
- gabapentine CI watch — Atom
- gabapentine CI watch — JSON
- gabapentine alone — RSS
Cite this brief
Drug Landscape (2026). gabapentine — Competitive Intelligence Brief. https://druglandscape.com/ci/gabapentine. Accessed 2026-05-14.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab